Pioneer in phage-based diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations
Menu
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations

Novel PCR reaction bead extends global reach of active TB test by removing the cold chain

Tuberculosis testing and treatment needs to happen close to the point of infection. PBD Biotech has developed a lyophilized PCR reaction bead for its Actiphage® blood test for active TB. This enables ambient shipping without the need for a cold chain, which reduces the cost of shipment and extends the shelf-life for components of the test.
  • March 17, 2023
  • Human health, Latest, Press release
PCR bead

Products that contain enzymes are temperature-sensitive and require cold chain transport to ensure their functional integrity. Lyophilization is a water removal process that can be used to extend shelf-life.

Joely Irlam, Chief Technology Officer for PBD Biotech, explains: “Although lyophilized products for drugs and food aren’t unusual, using this technology for a PCR product is novel. It is expensive and time consuming to re-develop the product in a lyophilised format and to ensure that sensitivity and specificity aren’t compromised.”

“PBD has addressed this pain early doors to ensure the product aligns with the WHO Target Product Profile (TPP) and allows an extension of shelf-life, which is always good for the customer.”

PBD has developed PCR primers and probes that allow specific detection of DNA lysed from Mycobacteria tuberculosis (Mtb) isolated from a human whole blood sample. The beads will contain polymerase enzyme, UNG enzyme to prevent contamination, dNTPs, oligonucleotide primers and probes and PCR additives.

Joely continues: “The PCR has also been specially developed to target multiple sites within the relevant insertion elements in the MTBC rather than just one. This is a unique feature and improves the test’s ability to detect Mtb at levels much lower than previously achieved.

“The new bead offers easy ambient shipping. Cold chain transport can limit the distance and/or time a sample can be in transit without guaranteed replenishment, so the bead will extend the global reach of Actiphage.”

By enabling early detection of TB disease progression, Actiphage has the potential to break the cycle of infection – offering an exciting contribution to the WHO #EndTB initiative.

Jane Theaker, CEO of PBD Biotech, says that the early testing and treatment of patients who have the infection and are likely to progress to active disease before they pass on their infection is an important pillar of the #EndTB campaign, but there are other areas where Actiphage can also provide support.

She says: “Actiphage could also be used to enable the stratification of patients for new TB drugs and vaccine therapies in clinical trials. In this way, the effectiveness of treatments can be assessed much more efficiently, leading to improved targeted drugs and vaccines.

“Antimicrobial resistance is a growing concern for the treatment of TB. Actiphage could be used to monitor the effectiveness of drug treatments, ensuring that, once the infection is cleared from the blood, the drug treatment can be stopped. In this way the potential for antimicrobial resistance can be minimised. This safeguards drug treatments for future use in TB patients.”

Share:

Related posts

Loading...
Mycobacterium tuberculosis (from CDC) transmission-reducing effects

Could phage-based TB diagnostics determine transmission-reducing benefits of vaccines in phase 3 trials?

September 19, 2023
Conventional phase 3 trials do not provide key information about the overall effect of introducing a new tuberculosis vaccine programme and so are missing crucial information for policy makers, argue experts in a personal view in Lancet Microbe.
Mycobacterium tuberculosis (from CDC) transmission-reducing effects

Could phage-based TB diagnostics determine transmission-reducing benefits of vaccines in phase 3 trials?

September 19, 2023
Conventional phase 3 trials do not provide key information about the overall effect of introducing a new tuberculosis vaccine programme...
Maggie Throup MP (credit: Richard Townshend / House of Commons)

Maggie Throup MP, chair of Diagnostics APPG, to meet leading UK diagnostic companies

September 13, 2023
PBD Biotech is one of the companies represented at a parliamentary reception organised by the British In Vitro Diagnostics Association (BIVDA)
Maggie Throup MP (credit: Richard Townshend / House of Commons)

Maggie Throup MP, chair of Diagnostics APPG, to meet leading UK diagnostic companies

September 13, 2023
PBD Biotech is one of the companies represented at a parliamentary reception organised by the British In Vitro Diagnostics Association...
Actiphage TB awarded US Patent grant for diagnostic kit

Actiphage TB awarded US Patent grant for diagnostic kit

July 25, 2023
PBD Biotech, developers of Actiphage® TB, a ground-breaking phage-based diagnostic for laboratory tuberculosis testing, has today announced it has secured the grant of a US patent for its diagnostic kit.
Actiphage TB awarded US Patent grant for diagnostic kit

Actiphage TB awarded US Patent grant for diagnostic kit

July 25, 2023
PBD Biotech, developers of Actiphage® TB, a ground-breaking phage-based diagnostic for laboratory tuberculosis testing, has today announced it has secured...
Leicester Respiratory Biomedical Research Unit

Actiphage TB enters third clinical trial

July 6, 2023
Actiphage TB is to enter its third clinical trial, which is aimed at validating its utility as a tuberculosis diagnostic. The phage-based diagnostic has potential for detecting TB progression.
Leicester Respiratory Biomedical Research Unit

Actiphage TB enters third clinical trial

July 6, 2023
Actiphage TB is to enter its third clinical trial, which is aimed at validating its utility as a tuberculosis diagnostic....
1 2 … 10 Next »

developers of phage-based diagnostics

Contact Us

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

BIVDA member 2023
Twitter Youtube Linkedin

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house